BioStock: Chordate Medical's CEO comments on the terminated study
Chordate Medical has for a longer period of time conducted two parallel studies – one in rhinitis (chronic nasal congestion) and one in chronic migraine – with the company’s technology Kinetic Oscillation Stimulation. Chordate Medical has now chosen to suspend recruitment for the rhinitis study as an interim analysis has shown that it will probably not reach conclusive end results. BioStock has contacted Chordate Medical’s CEO Anders Weilandt, who points out that the migraine indication is the company’s main focus right now and that sales of the company’s product are not affected by the announcement.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se